[2]Zhang LH, Song GH, Shao B, et al. The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis[J]. Anticancer Drugs, 2022, 33(1):e635-e643. doi: 10.1097/CAD...
Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18):a randomised phase 2 study. Lancet Oncol...
[2]Zhang LH, Song GH, Shao B, et al. The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis[J]. Anticancer Drugs, 2022, 33(1):e635-e643. doi: 10.1097/CAD...
研究者们总结,在这一II期试验中,在来曲唑方案中增加palbociclib可以明显延长雌激素受体阳性和HER2阴性的晚期乳腺癌患者的生存期。目前III期试验正在进行当中。 编译自:Palbociclib/Letrozole Improves Progression-Free Survival inFirst-Line Treatment of Estrogen Receptor–Positive/HER2-NegativeAdvanced Breast Cancer.THE...
[3]Oliveira M, Pominchuck D, Nowecki Z, et al Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. 2022 SABCS. Abstract GS3-02. ...
在乳腺癌研究中,ER和Her2状态是指导临床决策的重要风向标。进一步细分,在ER+HER2-患者中,21基因检测(Oncotype Dx Recurrence Score, Genomic Health)是研究的热点,可以帮助我们挑选出能真正从辅助化疗中获益的患者,同时对于低复发风险患者,可以规避化疗。 OncoType DX 复发风险评分介绍:...
Objective: This article aims to discuss elacestrant, an oral selective estrogen receptor downregulator approved by the Food and Drug Administration (FDA) in January 2023 for the treatment of hormone receptor positive (HR ) human epidermal growth factor receptor 2 negative (...
[18] Purrington KS, Gorski D, Simon MS, et al. Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers[J]. Breast Cancer Res Treat...
[10]Robertson J, Gogitidze T, Katashvili Z, et al. SERENA-3: A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive, HER2...
CACA CBCS指南建议对于Luminal-HER2阴性患者,若为中危且pN 0 ,T 1b-2 ,且存在ER弱阳性,则可考虑化疗 17 。 目前国内外指南态度并不一致,临床对于这部分乳腺癌患者的诊疗决策同样存在困惑。虽然我们当前的预测模型为ER弱阳性乳腺癌患者的再分型及治疗决策提供了思路,但由于该研究数据仅来自于同一机构,未能考量...